Hamlet Pharma’s achievements are emphasized after EU evaluation. The company has fully achieved its milestones and secured the second payment
We are proud to share the positive comments from the EIC Accelerator Horizon 2020 fund. The experienced EU evaluators state that: “All required milestones and deliverables to date are without any significant deviations. This is particularly impressive in light of the global Corona virus pandemic. To date, the beneficiary has succeeded in manufacturing the Investigational Medicinal Product (IMP) Alpa1H. The company has demonstrated non-clinical improvement of therapeutic efficacy of other cancer drugs like Mitomycin C and Epirubicin, when combined with Alpa1H and successfully continued